These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3166553)

  • 1. Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees.
    Goudsmit J; Thiriart C; Smit L; Bruck C; Gibbs CJ
    Vaccine; 1988 Jun; 6(3):229-32. PubMed ID: 3166553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Goudsmit J; Debouck C; Meloen RH; Smit L; Bakker M; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC
    Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4478-82. PubMed ID: 2454471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunodominant B-cell clones responsive to an HIV-1 neutralization and cell fusion inhibition epitope in chimpanzee-to-chimpanzee passages of HTLV-IIIB and LAV-1.
    Goudsmit J; Bakker M; Smit L
    Res Virol; 1989; 140(5):405-18. PubMed ID: 2479965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
    Nara PL; Robey WG; Arthur LO; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC; Fischinger PJ
    J Virol; 1987 Oct; 61(10):3173-80. PubMed ID: 2442411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction in chimpanzees of antibodies inhibiting receptor-mediated cell fusion by HIV glycoprotein.
    Goudsmit J; Smit L; Klaver B; Asher DM; Wolff A; Gibbs CJ; Gajdusek DC
    Viral Immunol; 1987-1988; 1(3):225-40. PubMed ID: 3509947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein.
    Matthews TJ; Langlois AJ; Robey WG; Chang NT; Gallo RC; Fischinger PJ; Bolognesi DP
    Haematol Blood Transfus; 1987; 31():414-22. PubMed ID: 2832276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrathecal and intrathecal IgG response to the AIDS virus LAV/HTLV-III in experimental infection of chimpanzees.
    Goudsmit J; Gibbs CJ; Asher DM; Gajdusek DC
    Cancer Detect Prev Suppl; 1987; 1():509-14. PubMed ID: 3480064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals.
    Devash Y; Matthews TJ; Drummond JE; Javaherian K; Waters DJ; Arthur LO; Blattner WA; Rusche JR
    AIDS Res Hum Retroviruses; 1990 Mar; 6(3):307-16. PubMed ID: 2340200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody recognition of amino acid divergence within an HIV-1 neutralization epitope.
    Goudsmit J; Zwart G; Bakker M; Smit L; Back N; Epstein L; Kuiken C; d'Amaro J; de Wolf F
    Res Virol; 1989; 140(5):419-36. PubMed ID: 2479966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
    Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
    J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine.
    Arthur LO; Pyle SW; Nara PL; Bess JW; Gonda MA; Kelliher JC; Gilden RV; Robey WG; Bolognesi DP; Gallo RC
    Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8583-7. PubMed ID: 3479807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.
    Prince AM; Horowitz B; Brotman B
    Lancet; 1986 Mar; 1(8483):706-10. PubMed ID: 2870224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120.
    Nara PL; Robey WG; Gonda MA; Carter SG; Fischinger PJ
    Proc Natl Acad Sci U S A; 1987 Jun; 84(11):3797-801. PubMed ID: 3473484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.
    Matthews TJ; Langlois AJ; Robey WG; Chang NT; Gallo RC; Fischinger PJ; Bolognesi DP
    Proc Natl Acad Sci U S A; 1986 Dec; 83(24):9709-13. PubMed ID: 2432599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.
    Nara PL; Robey WG; Pyle SW; Hatch WC; Dunlop NM; Bess JW; Kelliher JC; Arthur LO; Fischinger PJ
    J Virol; 1988 Aug; 62(8):2622-8. PubMed ID: 3392769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity of chimpanzee antibodies binding a strain-specific HIV-1 neutralization epitope of the external envelope.
    Goudsmit J; Bakker M; Smit L; Meloen RH
    J Med Primatol; 1989; 18(3-4):357-62. PubMed ID: 2474656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive assay for neutralizing antibodies against AIDS-related viruses (HTLV-III/LAV).
    Harada S; Purtilo DT; Koyanagi Y; Sonnabend J; Yamamoto N
    J Immunol Methods; 1986 Sep; 92(2):177-81. PubMed ID: 3639115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.
    Putney SD; Matthews TJ; Robey WG; Lynn DL; Robert-Guroff M; Mueller WT; Langlois AJ; Ghrayeb J; Petteway SR; Weinhold KJ
    Science; 1986 Dec; 234(4782):1392-5. PubMed ID: 2431482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of antibodies against LAV/HTLV III: comparative evaluation of four different commercial test kits.
    Abb J
    AIDS Res; 1986; 2(2):93-7. PubMed ID: 3013224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential neutralizing capacity to different human immunodeficiency virus (HIV) isolates by a rabbit antiserum against LAV: sensitive assays with HTLV-I-positive MT-4 cells.
    Yoshiyama H; Nakashima H; Kobayashi S; Yamamoto N
    AIDS Res Hum Retroviruses; 1988 Apr; 4(2):91-8. PubMed ID: 3284555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.